FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC Biotherapeutics, Inc.’s (“GTC”, Nasdaq: GTCB) total net loss for the third quarter ended September 28, 2008 was $6.1 million, or $0.06 per share, compared with $8.4 million, or $0.11 per share, in the third quarter of 2007. The total net loss for the first nine months of 2008 was $16.5 million, or $0.17 per share, compared to $26.5 million, or $0.34 per share, for the first nine months of 2007.
